Celyad SA ADR buy melinda
Start price
22.11.17
/
50%
€40.85
Target price
03.01.18
€55.02
Performance (%)
-3.67%
End price
03.01.18
€39.35
Summary
This prediction ended on 03.01.18 with a price of €39.35. With a performance of -3.67%, the BUY prediction for Celyad SA ADR by melinda closed slightly in the red. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celyad SA ADR | - | - | - | - |
| iShares Core DAX® | 0.437% | 5.897% | 8.047% | 65.579% |
| iShares Nasdaq 100 | 1.057% | 0.920% | 28.466% | 90.185% |
| iShares Nikkei 225® | 1.769% | 1.228% | 47.574% | 84.991% |
| iShares S&P 500 | 0.368% | 1.920% | 23.200% | 70.760% |
Comments by melinda for this prediction
In the thread Celyad SA ADR diskutieren
Biotechnologie und Medizintechnik SecteurRecherche Agenda 27/03 Ergebnis Publishing
Celyad ist ein biopharmazeutisches Unternehmen, die fortschrittliche Zellforschung nutzt innovative Therapien zu entwickeln und das Ergebnis von schweren Krankheiten zu verbessern. C-Cure ®, Kandidat der Celyad Flaggschiff-Produkt in Entwicklung gegen Herz-Kreislauf-Erkrankungen
(Vom Mitglied beendet)